Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BB Biotech has delivered strong long-term returns by investing in innovative public biotech firms developing novel therapeutics addressing significant unmet medical needs. Its concentrated approach favors high-conviction bets on small-to-mid-cap US and global biotechs with advanced or differentiated pipelines—especially those leveraging RNA-based technologies or cell/gene therapies. The fund has outperformed benchmarks over the past decade with a compound annual growth rate of ~17% and aims for at least a total return of ~15% per year.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BBRZ MED.